Literature DB >> 25847598

The role of Cas-L/NEDD9 as a regulator of collagen-induced arthritis in a murine model.

Tomoki Katayose1, Satoshi Iwata1, Naoki Oyaizu2, Osamu Hosono3, Taketo Yamada4, Nam H Dang5, Ryo Hatano1, Hirotoshi Tanaka6, Kei Ohnuma7, Chikao Morimoto6.   

Abstract

Cas-L/NEDD9 is a cytoplasmic docking protein downstream of β1 integrin-mediated signaling pathway and is essential for cellular migration and β1 integrin-mediated costimulation of T cells. We previously found that increased number of Cas-L positive leukocytes migrated into the inflamed joints of HTLV-I tax transgenic mice which spontaneously develop polyarthritis, suggesting a role of Cas-L in rheumatoid arthritis (RA) pathophysiology. Our current study expanded these findings on the role of Cas-L/NEDD9 in the development of RA by analyzing the pathophysiological changes in a Nedd9(-/-) mouse collagen-induced arthritis (CIA) model. Nedd9(-/-) mice exhibited a decrease in arthritis severity as compared to Nedd9(+/+) mice. In addition, as being conducted bone marrow transplantation experiments with a CIA model, Nedd9(-/-)→Nedd9(+/+) transplant showed a decrease in the incidence and severity score of arthritis, compared to those of Nedd9(+/+)→Nedd9(-/-) transplant. For analysis of serum levels of various cytokines, IL-1β, IL-6, IL-17, TNF-α, IFN-γ and anti-collagen antibody were decreased, while IL-4 and IL-10 levels were increased, in Nedd9(-/-) mice as compared to those in Nedd9(+/+) mice. Furthermore, collagen-mediated cellular responses of lymphocytes isolated from spleen or affected lymph nodes of Nedd9(-/-) mice were reduced. Our results strongly suggest that Cas-L/NEDD9 plays a pivotal role in the pathophysiology of CIA, and that Cas-L/NEDD9 may be a potential molecular target for the treatment of RA.
Copyright © 2015 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Cas-L/NEDD9; Collagen-induced arthritis; IL-10; Rheumatoid arthritis; T cell

Mesh:

Substances:

Year:  2015        PMID: 25847598     DOI: 10.1016/j.bbrc.2015.03.156

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  3 in total

1.  NEDD9 targets COL3A1 to promote endothelial fibrosis and pulmonary arterial hypertension.

Authors:  Andriy O Samokhin; Thomas Stephens; Bradley M Wertheim; Rui-Sheng Wang; Sara O Vargas; Lai-Ming Yung; Minwei Cao; Marcel Brown; Elena Arons; Paul B Dieffenbach; Jason G Fewell; Majed Matar; Frederick P Bowman; Kathleen J Haley; George A Alba; Stefano M Marino; Rahul Kumar; Ivan O Rosas; Aaron B Waxman; William M Oldham; Dinesh Khanna; Brian B Graham; Sachiko Seo; Vadim N Gladyshev; Paul B Yu; Laura E Fredenburgh; Joseph Loscalzo; Jane A Leopold; Bradley A Maron
Journal:  Sci Transl Med       Date:  2018-06-13       Impact factor: 17.956

2.  Alteration of N6-methyladenosine epitranscriptome profile in lipopolysaccharide-induced mouse mesangial cells.

Authors:  Tao Liu; Xing Xing Zhuang; Xiu Juan Qin; Liang Bing Wei; Jia Rong Gao
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2022-02-04       Impact factor: 3.000

3.  Identification of Nedd9 as a TGF-β-Smad2/3 Target Gene Involved in RANKL-Induced Osteoclastogenesis by Comprehensive Analysis.

Authors:  Yasunori Omata; Shinya Nakamura; Takuma Koyama; Tetsuro Yasui; Jun Hirose; Naohiro Izawa; Takumi Matsumoto; Yuuki Imai; Sachiko Seo; Mineo Kurokawa; Shuichi Tsutsumi; Yuho Kadono; Chikao Morimoto; Hiroyuki Aburatani; Takeshi Miyamoto; Sakae Tanaka
Journal:  PLoS One       Date:  2016-06-23       Impact factor: 3.240

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.